The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

NCI BSA approves nine new and reissued concepts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The NCI Board of Scientific Advisors approved nine new and reissued concepts at a meeting held March 28-29.

Also at the meeting, NCI Director Ned Sharpless—who recently announced that he would step down April 29—discussed the state of FY22 funding and President Joe Biden’s reinvigorated Moonshot (The Cancer Letter, Apr. 1, Apr. 4, 2022). 

Douglas Lowy, principal deputy director of NCI, delivered a presentation on how the FY22 NCI budget will affect research project grant paylines (The Cancer Letter, Apr. 1, 2022). Paylines for R01 grants for new and established investigators will stay at the 11th percentile, complicating NCI’s goal of reaching the 15th percentile by 2025. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthPodcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
By Robert A. Winn, Otis W. Brawley and Preston Willett
PodcastThe Directors

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
By Paul Goldberg and Claire Marie Porter
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account